Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1005 alone and with pembrolizumab in advanced solid tumors including MSI-H/dMMR tumors
2026-525248-13-00Phase 2Authorised
- Sponsor
- Eikon Therapeutics
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 22
01
Overview
Phase 2, open-label trial of EIK1005 and pembrolizumab in Nonhematologic neoplasms and microsatellite instability-high cancer (3 arms), sponsored by Eikon Therapeutics. Primary endpoints: Dose-limiting toxicities and adverse events and Adverse events. Planned start Jul 2026; status: authorised.
02
Drugs
EIK1005pembrolizumab
03
Conditions
Nonhematologic neoplasmsmicrosatellite instability-high cancer
Beyond the preview
Go deeper on 2026-525248-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525248-13-00.